Thyrotoxic Periodic Paralysis: A Case Report and Literature Review

M. J. Barahona; I. Vinagre; L. Sojo; J. M. Cubero; and Antonio Pérez

Reprint Requests:
Antonio Pérez
Department of Endocrinology
Hospital Sant Pau
S. Antoni M. Claret 167, 08025
Barcelona, Spain
Tel: +34 93-5565661
Fax: +34 93 5565727
E-mail: aperez@santpau.cat

Received: August 25, 2008
Revised: January 6, 2009
Accepted: January 30, 2009
doi:10.3121/cmr.2009.816
Abstract

We describe a 37-year-old man with a 4-month history of episodic muscular weakness, involving mainly lower-limbs. Hypokalemia was documented in one episode and managed with intravenous potassium chloride. Hyperthyroidism was diagnosed 4 months after onset of attacks because of mild symptoms. The patient was subsequently diagnosed as having thyrotoxic periodic paralysis associated with Graves’ disease. Treatment with propranolol and methimazol was initiated and 1 year later he remains euthyroid and symptoms free. Thyrotoxic periodic paralysis is a rare disorder, especially among Caucasians, but it should always be considered in patients with acute paralysis and hypokalemia, and thyroid function should be evaluated.

Keywords: Hyperthyroidism; Hypokalemia; Thyrotoxic periodic paralysis
Thyrotoxic periodic paralysis (TPP) is a rare complication of hyperthyroidism characterized by episodes of muscle weakness and hypokalemia. TPP is often not recognized at first attack due to a very low prevalence among the Caucasian population and usually mild symptoms of hyperthyroidism. We report a case of TPP due to Graves’ disease in a Caucasian male, who presented with 4 paralytic episodes before the diagnosis was made.

**Case Report**

A 37-year-old Caucasian man was admitted at the hospital for evaluation of episodic muscular weakness. He recalled four similar episodes in the previous 4 months, which started during sleep or post-exercise rest. Attacks consisted of flaccid muscle weakness that varied from mild proximal leg weakness to quadriplegia, involving mainly the lower-limbs. Three attacks resolved spontaneously over 2-8 hours. Hypokalemia (2.3 mEq/L) and mild hypomagnesemia (1.53 mg/dL) were documented in one episode and managed with administration of intravenous potassium chloride in the emergency department. In this attack, proximal flaccid quadriplegia 2/5 was observed, with normal reflexes and sensory examination. The electrocardiogram was normal.

Two weeks later (between episodes) laboratory studies revealed normal renal and hepatic function, and the following results: serum sodium 143 mEq/L (136-145), potassium 3.6 mEq/L (3.50-5.10), calcium 9.03 mg/dL (8.27-9.80), albumin 34.5 g/L (34-48), urine sodium 77 mEq/L (25-150), urine potassium 93 mEq/L (17-83). He had no significant personal or familial medical history and he was not taking any medication. He related weight loss, distal tremor, and heat intolerance for 3 to 4 months. On admission, blood pressure was 130/70 mmHg and heart-rate 75 beats/minute. Physical examination revealed a slightly enlarged
thyroid gland without nodules, fine resting tremor of the hands, and mild proximal lower limb weakness. No exophthalmus or skin changes were present. Thyroid stimulating hormone level was <0.03 µU/mL (0.25-5.0), free thyroxin level 3.14 ng/dL (0.77-1.71), and free triiodothyronine 1.44 ng/dL (0.23-0.39). Thyroid radioiodine uptake was 48% at 2 hours and 72% at 24 hours, and scan revealed a diffuse homogeneous uptake. The patient was diagnosed as having thyrotoxic periodic hypokalemic paralysis associated with Graves’ thyrotoxicosis. Treatment with propranolol and methimazole was initiated (see table). After 1 year of follow-up the patient remains euthyroid and symptom free.

**Discussion**

The present case describes a Caucasian patient suffering from TPP due to Graves’ disease. TPP is an uncommon and potentially life-threatening complication of thyrotoxicosis characterized by acute and reversible episodes of muscle weakness and hypokalemia. It occurs in about 0.1% to 0.2% of the hyperthyroid population in North America and it is 10 times more frequent in the Oriental population and in males. The age of onset is usually in the third decade of life. The high incidence of this disorder in Asians and the association with the presence of HLA-DRw8 suggests that the basic defect may be genetically determined, but the precise pathogenesis of TPP remains unclear. Although the association with HLA system may suggest an immunogenetic etiology of the TPP, some patients have thyrotoxicosis without an autoimmune mechanism, such as Jod-Basedow phenomenon, thyroiditis, thyroid stimulating hormone-secreting pituitary tumor, abuse of thyroid hormone, solitary toxic thyroid adenoma, and amiodarone-induced thyrotoxicosis. Although episodes of paralysis are not correlated with the severity of the thyrotoxic state, it is known that resolution of TPP occurs once euthyroidism is restored, therefore, the presence of excessive thyroid hormones in serum seems necessary for this disorder. It has been shown...
that patients with TPP have a significantly higher Na-K-ATPase pump number and activity than healthy subjects or thyrotoxic patients without a history of paralysis. Thyroid hormone, β-adrenergic catecholamine, and insulin can increase the pump activity in skeletal muscles, liver, or kidneys. This leads to a shift of potassium into the cells, manifested as low serum potassium, as seen in our patient, but without changing the total body potassium level. This may explain why weakness resolves when potassium returns to the extracellular space.

Hypophosphatemia and hypomagnesemia have also been reported and may contribute to the muscle weakness. Finally, the attacks of paralysis tend to occur during the night, as in our patient, and after stress, alcohol intake, or a carbohydrate-rich meal, suggesting a possible role of hyperinsulinemia. It has also been described that therapy with glucocorticoid at high-dose, antiretroviral for AIDS, or interferon-alpha are possible precipitating factors.

A myopathic pattern during attacks of paralysis that disappeared during remission has been reported in electromyogram, while peripheral nerve function remains normal. There are also some case-reports which describe rhabdomyolysis associated with a severe attack of TPP. Vacuolation and mitochondrial abnormalities are the most common electron microscopic changes in skeletal muscles.

Diagnosis of TPP is based on clinical and biochemical evidence of hyperthyroidism and hypokalemia in a patient with a history of recurrent episodes of proximal muscle weakness, affecting mainly the lower limbs, without a family history of this disorder. The severity of attacks varies from mild weakness to quadriplegia or total paralysis. Bulbar, respiratory, and ocular muscles are rarely affected. In the majority of patients, deep tendon reflexes are markedly diminished or absent. Cognitive and sensory functions remain normal. The onset of paralytic attacks usually coincides with the onset of hyperthyroidism, although symptoms, if
Some electrocardiogram features that can suggest a diagnosis of TPP are the triad of sinus tachycardia attributable to the hyperadrenergic state, prolonged QT-U interval attributable to hypokalemia, and a paradoxically prolonged PR interval due to the thyrotoxicosis.\textsuperscript{12}

The differential diagnosis for TPP includes familial hypokalemic periodic paralysis (FHPP). Both disorders are identical in their clinical presentation, but TPP is rarely associated with a positive family history and has a later onset of presentation than FHPP.\textsuperscript{7,13} The recurrent attacks with normal plasma potassium levels between attacks distinguish periodic paralysis from other causes of hypokalemic paralysis. Moreover, mutations in the ionic channel genes such as CACNA1S, SCN4A and KCNE3 have been reported in the FHPP.\textsuperscript{5}

Definitive treatment of TPP consists in the management of thyrotoxicosis by medical therapy, surgery, or radioactive iodine therapy. Treatment of acute attack is potassium administration, but excessive doses of potassium can lead to hyperkalemia once potassium shifts to extracellular space.\textsuperscript{6} No correlation between potassium dose administered and recovery time was observed. To prevent attacks until euthyroid state is achieved, a useful therapy is the administration of a $\beta$-adrenergic blocker like propranolol. Other preventive measures that may be effective include a low-carbohydrate diet and potassium-sparing diuretics.\textsuperscript{13} Use of potassium supplements is not useful for prophylaxis against further paralytic attacks and it should not be given to patients between episodes.\textsuperscript{14}

**Conclusion**

In summary, episodes of periodic paralysis usually precede the diagnosis of thyroid dysfunction and does not recur once euthyroidism is achieved. Therefore, it is necessary that
an early diagnosis of TPP is made to administer definitive treatment and prevent morbidity and mortality, mainly due to fatal arrhythmias. The presence of acute paralysis, especially with hypokalemia, should prompt the clinician to consider TPP as a cause and evaluate thyroid function.
References


**Author Affiliations**

*M. J. Barahona*
Department of Endocrinology and Nutrition
Hospital Sant Pau
Autonomous University of Barcelona (UAB)
Spain

*I. Vinagre*
Department of Endocrinology and Nutrition
Hospital Sant Pau
Autonomous University of Barcelona (UAB)
Spain

*L. Sojo*
Department of Endocrinology and Nutrition
Hospital Sant Pau
Autonomous University of Barcelona (UAB)
Spain

*J. M. Cubero*
Department of Endocrinology and Nutrition
Hospital Sant Pau
Autonomous University of Barcelona (UAB)
Spain

*A. Pérez*
Department of Endocrinology and Nutrition
Hospital Sant Pau
Autonomous University of Barcelona (UAB)
Spain
Table 1. Main laboratory results on admission and during follow-up.

<table>
<thead>
<tr>
<th>Time since diagnosis</th>
<th>0 day</th>
<th>Month 2</th>
<th>Month 3</th>
<th>Month 4</th>
<th>Month 8</th>
<th>Month 11</th>
<th>Month 14</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thyrotropine (μU/mL)</td>
<td>&lt;0.03</td>
<td>2.16</td>
<td>25.8</td>
<td>4.43</td>
<td>3.43</td>
<td>3.23</td>
<td>0.82</td>
</tr>
<tr>
<td>Free thyroxine (ng/dL)</td>
<td>3.14</td>
<td>0.44</td>
<td>0.19</td>
<td>0.85</td>
<td>0.99</td>
<td>1.13</td>
<td></td>
</tr>
<tr>
<td>Free triiodothyronine (ng/dL)</td>
<td>1.44</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methimazole dose (mg/d)</td>
<td>0</td>
<td>60</td>
<td>20</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>Serum potassium (mEq/L)</td>
<td>4.38</td>
<td>4.52</td>
<td>4.19</td>
<td>4.7</td>
<td>4.38</td>
<td>4.6</td>
<td></td>
</tr>
</tbody>
</table>

0 day, on admission.
Normal reference levels: thyrotropine: 0.25-5.0 μU/mL; free thyroxine: 0.77-1.71 ng/dL; free triiodothyronine: 0.23-0.39 ng/dL.